Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GST049
MIFTS: 62

Gastrointestinal System Cancer

Categories: Cancer diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gastrointestinal System Cancer

About this section

MalaCards integrated aliases for Gastrointestinal System Cancer:

Name: Gastrointestinal System Cancer 12 15
Digestive System Neoplasms 45 74
Gastrointestinal Neoplasms 45 74
Malignant Neoplasm of Gastrointestinal Tract 74
Gastrointestinal Tract Cancer 12
Digestive System Carcinoma 17
Cancer of Digestive System 74
Digestive System Neoplasm 17
Digestive System Cancer 12
Gi Tumor 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:3119
ICD9CM 36 239.0
NCIt 51 C3052 C4890
SNOMED-CT 69 93811007
ICD10 34 C26.9
Sources

Summaries for Gastrointestinal System Cancer

About this section
Disease Ontology : 12 An organ system cancer located in gastrointestinal tract that is manifested in organs of the gastrointestinal system.

MalaCards based summary : Gastrointestinal System Cancer, also known as digestive system neoplasms, is related to oral cavity cancer and pharynx cancer, and has symptoms including signs and symptoms, digestive An important gene associated with Gastrointestinal System Cancer is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Oxaliplatin and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and pancreas, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Gastrointestinal System Cancer

About this section

Diseases related to Gastrointestinal System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 214)
# Related Disease Score Top Affiliating Genes
1 oral cavity cancer 32.4 CDH1 EGFR TP53 VEGFA
2 pharynx cancer 32.2 AKT1 CASP3 CCND1 CDH1 CTNNB1 EGFR
3 esophageal cancer 32.0 AKT1 CASP3 CCND1 CDH1 CTNNB1 EGFR
4 gastric cancer 32.0 AFP AKT1 BANCR CASP3 CCND1 CDH1
5 small cell cancer of the lung 30.6 AKT1 EGFR HOTAIR KIT MALAT1 TP53
6 ovarian cancer 1 30.6 AKT1 CDH1 KRAS TP53 VEGFA
7 lynch syndrome 30.5 CCND1 CTNNB1 EGFR KRAS MLH1 TP53
8 familial adenomatous polyposis 30.4 CCND1 CDH1 CTNNB1 KRAS MLH1 TP53
9 squamous cell carcinoma 30.3 AKT1 CCND1 CDH1 CTNNB1 EGFR H19
10 pancreatic cancer 30.2 AKT1 CASP3 CCND1 CDH1 CTNNB1 EGFR
11 adenocarcinoma 30.2 AKT1 CCND1 CDH1 CTNNB1 EGFR H19
12 ovarian cancer 30.2 AKT1 CASP3 CCND1 CDH1 CTNNB1 EGFR
13 lung cancer 30.1 AKT1 BANCR CASP3 CCND1 CDH1 EGFR
14 gastric adenocarcinoma 30.1 AFP AKT1 BANCR CASP3 CCND1 CDH1
15 gastrointestinal neuroendocrine tumor 11.0
16 gastrointestinal carcinoma 11.0
17 esophagus squamous cell carcinoma 10.7 BANCR HOTAIR
18 undifferentiated embryonal sarcoma of the liver 10.7 MALAT1 SERPINA3
19 adult hepatocellular carcinoma 10.7 CTNNB1 TP53
20 urachal adenocarcinoma 10.7 AFP KRAS
21 apocrine adenoma 10.7 HRAS KRAS
22 cerebral convexity meningioma 10.7 CDH1 TP53
23 thymoma, familial 10.7 HRAS KIT
24 brain ependymoma 10.7 EGFR TP53
25 short-rib thoracic dysplasia 4 with or without polydactyly 10.7 CASP3 TP53
26 pancreatic ductal adenocarcinoma 10.7 H19 HOTAIR MALAT1
27 mixed germ cell tumor 10.7 AFP KIT
28 intravascular papillary endothelial hyperplasia 10.7 SERPINA3 VEGFA
29 malignant anus melanoma 10.7 ADAM17 KIT
30 small intestine leiomyosarcoma 10.7 ADAM17 KIT
31 small intestinal sarcoma 10.7 ADAM17 KIT
32 pharynx squamous cell carcinoma 10.7 AKT1 CASP3
33 lower lip cancer 10.7 CASP3 MLH1
34 leukemia, chronic lymphocytic 2 10.7 HRAS KRAS TP53
35 dermatofibrosarcoma protuberans 10.7 KIT SERPINA3 TP53
36 germ cell cancer 10.7 AFP H19 KIT
37 histiocytoma 10.7 KIT SERPINA3 TP53
38 renal cell carcinoma, papillary, 1 10.7 HRAS KIT TP53
39 ovarian serous cystadenocarcinoma 10.7 AKT1 HRAS TP53
40 li-fraumeni syndrome 10.7 EGFR MLH1 TP53
41 sarcoma, synovial 10.7 CDH1 CTNNB1 KIT
42 familial colorectal cancer 10.7 CDH1 MLH1 TP53
43 peripheral nervous system neoplasm 10.7 AKT1 CASP3 TP53
44 autosomal genetic disease 10.7 MLH1 TP53 VEGFA
45 malignant peripheral nerve sheath tumor 10.7 EGFR KIT TP53
46 inflammatory myofibroblastic tumor 10.7 CCND1 KIT TP53
47 autonomic nervous system neoplasm 10.7 AKT1 CASP3 TP53
48 grade iii astrocytoma 10.7 EGFR TP53 VEGFA
49 ovarian epithelial cancer 10.7 H19 HOTAIR MALAT1
50 liver disease 10.7 AFP AKT1 CASP3 SERPINA3

Comorbidity relations with Gastrointestinal System Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Cholestasis Deficiency Anemia
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Gastrointestinal System Cancer:



Diseases related to Gastrointestinal System Cancer
Sources

Symptoms & Phenotypes for Gastrointestinal System Cancer

About this section

UMLS symptoms related to Gastrointestinal System Cancer:


signs and symptoms, digestive

GenomeRNAi Phenotypes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

27 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.29 EGFR HRAS KRAS
2 Decreased viability GR00106-A-0 10.29 KRAS
3 Decreased viability GR00221-A-1 10.29 AKT1 CDH1 EGFR HRAS KIT KRAS
4 Decreased viability GR00221-A-2 10.29 AKT1 HRAS KRAS
5 Decreased viability GR00221-A-3 10.29 AKT1 HRAS
6 Decreased viability GR00221-A-4 10.29 AKT1 EGFR
7 Decreased viability GR00301-A 10.29 CDH1 KIT KRAS
8 Decreased viability GR00381-A-1 10.29 KRAS
9 Decreased viability GR00402-S-2 10.29 AKT1 CDH1 EGFR HRAS KIT KRAS
10 Decreased cell migration GR00055-A-1 9.73 ADAM17 AKT1 CTNNB1 EGFR HRAS KRAS
11 Increased cell migration GR00055-A-3 9.35 ADAM17 CTNNB1 EGFR HRAS KRAS
12 Reduced mammosphere formation GR00396-S 9.28 ADAM17 AFP CCND1 CCR6 CDH1 EGFR

MGI Mouse Phenotypes related to Gastrointestinal System Cancer:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.44 ADAM17 AFP AKT1 CASP3 CCND1 CDH1
2 homeostasis/metabolism MP:0005376 10.44 ADAM17 AFP AKT1 CASP3 CCND1 CCR6
3 cardiovascular system MP:0005385 10.41 ADAM17 AKT1 CASP3 CCND1 CDH1 CTNNB1
4 cellular MP:0005384 10.4 ADAM17 AKT1 CASP3 CCND1 CDH1 CTNNB1
5 digestive/alimentary MP:0005381 10.39 ADAM17 CASP3 CCND1 CDH1 CTNNB1 EGFR
6 growth/size/body region MP:0005378 10.37 ADAM17 AKT1 CASP3 CCND1 CDH1 CTNNB1
7 immune system MP:0005387 10.37 ADAM17 AKT1 CASP3 CCND1 CCR6 CDH1
8 integument MP:0010771 10.36 ADAM17 AKT1 CASP3 CCND1 CDH1 CTNNB1
9 mortality/aging MP:0010768 10.36 ADAM17 AFP AKT1 CASP3 CCND1 CDH1
10 hematopoietic system MP:0005397 10.35 ADAM17 AKT1 CASP3 CCND1 CCR6 CTNNB1
11 craniofacial MP:0005382 10.27 CASP3 CCND1 CTNNB1 EGFR HRAS KIT
12 embryo MP:0005380 10.26 ADAM17 AKT1 CDH1 CTNNB1 EGFR KIT
13 neoplasm MP:0002006 10.26 AFP AKT1 CCND1 CDH1 CTNNB1 EGFR
14 nervous system MP:0003631 10.23 ADAM17 AKT1 CASP3 CCND1 CCR6 CTNNB1
15 normal MP:0002873 10.18 ADAM17 AKT1 CCND1 CCR6 CDH1 CTNNB1
16 muscle MP:0005369 10.15 ADAM17 AKT1 CASP3 CTNNB1 EGFR KIT
17 liver/biliary system MP:0005370 10.13 AFP AKT1 CTNNB1 EGFR KIT KRAS
18 no phenotypic analysis MP:0003012 10.09 CASP3 CDH1 CTNNB1 EGFR HRAS KIT
19 limbs/digits/tail MP:0005371 10.08 ADAM17 CTNNB1 EGFR KIT KRAS TP53
20 reproductive system MP:0005389 10.07 ADAM17 AFP AKT1 CASP3 CCND1 CDH1
21 hearing/vestibular/ear MP:0005377 10.06 CASP3 CTNNB1 EGFR KIT KRAS TP53
22 respiratory system MP:0005388 9.93 ADAM17 AKT1 CASP3 CCND1 CTNNB1 EGFR
23 renal/urinary system MP:0005367 9.92 CASP3 CTNNB1 EGFR HRAS KIT KRAS
24 pigmentation MP:0001186 9.91 ADAM17 CASP3 CTNNB1 EGFR KIT KRAS
25 skeleton MP:0005390 9.7 ADAM17 AKT1 CASP3 CCND1 CTNNB1 EGFR
26 vision/eye MP:0005391 9.32 ADAM17 CASP3 CCND1 CTNNB1 EGFR KIT
Sources

Drugs & Therapeutics for Gastrointestinal System Cancer

About this section

Drugs for Gastrointestinal System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1184)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
2
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169590-42-5 2662
3
Tramadol Approved, Investigational Phase 4,Phase 3,Not Applicable 27203-92-5 33741
4
Parecoxib Approved Phase 4,Phase 3,Not Applicable 198470-84-7
5
Fluorouracil Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
6
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
7
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81103-11-9 84029
8
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2 117976-89-3 5029
9
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
10
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 100286-90-6, 97682-44-5 60838
11
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 137-58-6 3676
12
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-43-4 5816
13
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 329-65-7 838
14
Levobupivacaine Approved, Investigational Phase 4,Not Applicable 27262-47-1 92253
15
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 437-38-7 3345
16
Pantoprazole Approved Phase 4,Phase 2,Not Applicable 102625-70-7 4679
17
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
18
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 154361-50-9 60953
19
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 56420-45-2 41867
20
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
21 Ethiodized oil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 8008-53-5
22
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112887-68-0 104758
23
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 114-07-8 441411 12560
24
Tegafur Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 17902-23-7 5386
25
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 216974-75-3
26
Levoleucovorin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 68538-85-2
27
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
28
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 27284 23925
29
Bisacodyl Approved Phase 4,Not Applicable 603-50-9
30
Cetuximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 205923-56-4 56842117 2333
31
Phylloquinone Approved, Investigational Phase 4,Phase 2 84-80-0
32 Menaquinone Approved, Investigational Phase 4,Phase 2 1182-68-9
33
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 124-94-7 31307
34
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7553-56-2 807
35
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
36
Pravastatin Approved Phase 4,Phase 2 81093-37-0 54687
37
Hydromorphone Approved, Illicit Phase 4,Phase 3,Not Applicable 466-99-9 5284570
38
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 76-42-6 5284603
39
Methadone Approved, Illicit Phase 4,Phase 1,Phase 2,Not Applicable 76-99-3 4095
40
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
41
Gabapentin Approved, Investigational Phase 4,Phase 2,Not Applicable 60142-96-3 3446
42
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
43
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38396-39-3, 2180-92-9 2474
44
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
45
Ketorolac Approved Phase 4,Phase 1,Not Applicable 74103-06-3, 66635-83-4 3826
46
Ketamine Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 6740-88-1 3821
47
Orphenadrine Approved Phase 4 83-98-7 4601
48
Acetaminophen Approved Phase 4,Phase 2,Phase 1,Not Applicable 103-90-2 1983
49
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53608-75-6
50
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051

Interventional clinical trials:

(show top 50) (show all 10086)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
3 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
4 Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma Unknown status NCT02860429 Phase 4 Cinobufacini injection;chemotherapy
5 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication Unknown status NCT03134378 Phase 4 Rabeprazole Sodium 20mg;Clarithromycin 500mg;Amoxicillin 500 Mg
6 Nutritional Supplementation in Patients With no Signs of Malnutrition Unknown status NCT01894828 Phase 4
7 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
8 A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy Unknown status NCT02776527 Phase 4 Apatinib Mesylate Tablets
9 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
10 Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX Unknown status NCT02609425 Phase 4
11 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Unknown status NCT02426034 Phase 4 Apatinib
12 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer Unknown status NCT02401971 Phase 4 Thalidomide;CPT-11
13 Postoperative Pain Management After Minimally Invasive Esophagectomy Unknown status NCT02042313 Phase 4
14 Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients Unknown status NCT01910948 Phase 4 omega-3 polyunsaturated fatty acids
15 Early Jejunostomy Nutrition Minimizes Time to Chemotherapy Unknown status NCT01766765 Phase 4
16 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
17 Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Unknown status NCT02575378 Phase 4 Metronimic chemotherapy plus Chinese Traditional Medicine;Metronimic chemotherapy
18 Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
19 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
20 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
21 Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
22 Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01972490 Phase 4 avastin+chemotherapy of mFOLFOX6 or FOLFIRI;chemotherapy of mFOLFOX6 or FOLFIRI
23 Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Unknown status NCT01959061 Phase 4 Raltitrexed;Oxaliplatin;lipiodol
24 Iron Replacement in Oesophagogastric Neoplasia Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
25 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
26 Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery Unknown status NCT00757640 Phase 4
27 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
28 Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep Unknown status NCT01695863 Phase 4 comparing 2 drugs on their effect on the bowel preparation for colonoscopy
29 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
30 A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer Unknown status NCT02887365 Phase 4 tegafur-uracil
31 Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
32 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
33 New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
34 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
35 Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
36 Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Unknown status NCT00868569 Phase 4
37 Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
38 Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
39 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
40 Preoperative Assessment of Colon Tumor Unknown status NCT00114829 Phase 4
41 Intravenous Iron for Correction of Anaemia After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
42 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
43 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
44 Radiofrequency in the Treatment of Barrett's Oesophagus Unknown status NCT02558504 Phase 4
45 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
46 Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE Unknown status NCT02557503 Phase 4 Oxaliplatin and fluorouracil
47 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
48 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
49 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
50 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4

Search NIH Clinical Center for Gastrointestinal System Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: digestive system neoplasms

Sources

Genetic Tests for Gastrointestinal System Cancer

About this section
Sources

Anatomical Context for Gastrointestinal System Cancer

About this section

MalaCards organs/tissues related to Gastrointestinal System Cancer:

42
Liver, Colon, Pancreas, Testes, Lung, Breast, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Gastrointestinal System Cancer:

20
Gastrointestinal Tract
Sources

Publications for Gastrointestinal System Cancer

About this section

Articles related to Gastrointestinal System Cancer:

# Title Authors Year
1
Efficacy and safety of sodium cantharidinate and vitamin B6 injection for the treatment of digestive system neoplasms: a meta-analysis of randomized controlled trials. ( 30643386 )
2019
2
ncRNAs associated with drug resistance and the therapy of digestive system neoplasms. ( 30941775 )
2019
3
The effect of chemotherapy on nutritional status and weakness in geriatric gastrointestinal system cancer patients. ( 29429533 )
2018
4
Solute carrier transporters: potential targets for digestive system neoplasms. ( 29416375 )
2018
5
Associations of the IL-17A rs2275913 and IL-17F rs763780 polymorphisms with the risk of digestive system neoplasms: A meta-analysis. ( 30562686 )
2018
6
The effect of intraoperative hypothermia upon blood transfusion needs and length of stay among gastrointestinal system cancer surgery. ( 28417506 )
2017
7
Prognostic Value of NME1 (NM23-H1) in Patients with Digestive System Neoplasms: A Systematic Review and Meta-Analysis. ( 27518571 )
2016
8
Prognostic Value of MACC1 in Digestive System Neoplasms: A Systematic Review and Meta-Analysis. ( 26090393 )
2015
9
Perioperative immunonutrition ameliorates the postoperative immune depression in patients with gastrointestinal system cancer (prospective clinical study in 42 patients). ( 15587331 )
2004
10
Streptococcus bovis bacteremia and digestive system neoplasms. ( 3194717 )
1988
Sources

Variations for Gastrointestinal System Cancer

About this section
Sources

Expression for Gastrointestinal System Cancer

About this section
Search GEO for disease gene expression data for Gastrointestinal System Cancer.
Sources

Pathways for Gastrointestinal System Cancer

About this section

Pathways related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 67
Show member pathways
 14.3 ADAM17 AKT1 CASP3 CCND1 CCR6 CDH1
2
Innate Immune System 67
Show member pathways
 14.13 ADAM17 AKT1 CASP3 CCND1 CCR6 CDH1
3
ERK Signaling 65
Show member pathways
 13.95 ADAM17 AKT1 CASP3 CCND1 CCR6 CDH1
4
TGF-Beta Pathway 65
Show member pathways
 13.64 AKT1 CDH1 EGFR HRAS KIT KRAS
5
Akt Signaling 65
Show member pathways
 13.53 AKT1 CASP3 CCND1 CCR6 EGFR HRAS
6
Integrin Pathway 65
Show member pathways
 13.52 AKT1 CASP3 CCR6 CTNNB1 EGFR HRAS
7
Cytokine Signaling in Immune system 67
Show member pathways
 13.46 ADAM17 AKT1 CASP3 CCND1 EGFR HRAS
8
PAK Pathway 65
Show member pathways
 13.42 AKT1 CASP3 CCR6 CDH1 CTNNB1 EGFR
9
Nanog in Mammalian ESC Pluripotency 65
Show member pathways
 13.4 AKT1 CASP3 CDH1 CTNNB1 EGFR HRAS
10
IL-2 Pathway 65
Show member pathways
 13.33 ADAM17 AKT1 CCND1 EGFR HRAS KRAS
11
Phospholipase-C Pathway 65
Show member pathways
 13.17 AKT1 EGFR HRAS KIT KRAS TP53
12
G-Beta Gamma Signaling 65
Show member pathways
 13.14 AKT1 CTNNB1 EGFR HRAS KRAS VEGFA
13
fMLP Pathway 65
Show member pathways
 13.13 AKT1 CASP3 CDH1 CTNNB1 HRAS KRAS
14
Human cytomegalovirus infection 38
Show member pathways
 13.09 AKT1 CASP3 CCND1 CTNNB1 EGFR HRAS
15
TNFR1 Pathway 65
Show member pathways
 13.08 AKT1 CASP3 CTNNB1 EGFR HRAS KRAS
16
Development Angiotensin activation of ERK 23
Show member pathways
 13.05 AKT1 CASP3 EGFR HRAS KIT KRAS
17
Regulation of lipid metabolism Insulin signaling-generic cascades 23
Show member pathways
 13.03 ADAM17 AKT1 EGFR HRAS KRAS VEGFA
18
Focal Adhesion 1 38
Show member pathways
 13.03 AKT1 CCND1 CTNNB1 EGFR HRAS KRAS
19
PI3K-Akt signaling pathway 38
Show member pathways
 13.03 AKT1 CASP3 CCND1 CTNNB1 EGFR HRAS
20
Apoptosis Modulation and Signaling 1
Show member pathways
 12.91 AKT1 CASP3 HRAS KRAS TP53
21
MAPK signaling pathway 1 38
12.89 AKT1 CASP3 EGFR HRAS KIT KRAS
22
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.86 AKT1 EGFR HRAS KIT KRAS TP53
23
Vascular smooth muscle contraction 38
Show member pathways
 12.85 AKT1 CCND1 EGFR HRAS KRAS
24
Development HGF signaling pathway 23
Show member pathways
 12.84 AKT1 CASP3 CDH1 CTNNB1 HRAS KRAS
25
Ras signaling pathway 38
Show member pathways
 12.84 AKT1 CDH1 CTNNB1 EGFR HRAS KIT
26
Glioma 38
Show member pathways
 12.83 AKT1 CCND1 CDH1 EGFR HRAS KRAS
27
4-1BB Pathway 65
Show member pathways
 12.81 AKT1 CASP3 EGFR HRAS KRAS TP53
28
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.77 AKT1 CASP3 CCND1 CTNNB1 EGFR HRAS
29
Gastric cancer 38
Show member pathways
 12.77 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
30
Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases 23
Show member pathways
 12.75 ADAM17 AKT1 CCND1 CTNNB1 HRAS
31
Immune response IL-23 signaling pathway 23
Show member pathways
 12.73 AKT1 CTNNB1 EGFR HRAS KRAS TP53
32
ErbB signaling pathway 1 38
Show member pathways
 12.72 AKT1 CCND1 EGFR HRAS KRAS TP53
33
Endometrial cancer 38
Show member pathways
 12.68 AKT1 CASP3 CCND1 CDH1 CTNNB1 EGFR
34
MicroRNAs in cancer 38
12.65 CASP3 CCND1 EGFR HRAS KRAS TP53
35
mTOR signaling pathway (KEGG) 38
Show member pathways
 12.63 AKT1 EGFR HRAS KRAS TP53
36
Prolactin Signaling Pathway 1 38
Show member pathways
 12.61 AKT1 CASP3 CCND1 HRAS KRAS
37
Development EGFR signaling pathway 23
Show member pathways
 12.57 AKT1 CASP3 CCND1 CDH1 CTNNB1 EGFR
38
Arrhythmogenic right ventricular cardiomyopathy (ARVC) 38
Show member pathways
 12.56 CCND1 CTNNB1 EGFR HRAS KRAS
39
Apoptosis Pathway 73
Show member pathways
 12.56 AKT1 CASP3 CTNNB1 EGFR HRAS KRAS
40
WNT Signaling 65
12.55 AKT1 CCND1 CDH1 CTNNB1 TP53
41
VEGF Pathway (Qiagen) 65
Show member pathways
 12.54 AKT1 EGFR HRAS KRAS VEGFA
42
Phospholipase D signaling pathway 38
Show member pathways
 12.54 AKT1 EGFR HRAS KIT KRAS
43
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.53 AKT1 CCND1 HRAS TP53
44
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.53 AKT1 CCND1 EGFR HRAS KRAS
45
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.53 CDH1 CTNNB1 EGFR HRAS KIT KRAS
46
Development VEGF signaling via VEGFR2 - generic cascades 23
Show member pathways
 12.53 AKT1 CTNNB1 HRAS KRAS VEGFA
47
RhoGDI Pathway 65
Show member pathways
 12.49 CASP3 EGFR HRAS VEGFA
48
Development IGF-1 receptor signaling 23
Show member pathways
 12.49 AKT1 CCND1 HRAS TP53
49
Human T-cell leukemia virus 1 infection 38
12.49 AKT1 CCND1 CTNNB1 HRAS KRAS TP53
50
Pathways in cancer 38
12.46 AKT1 CASP3 CCND1 CDH1 CTNNB1 EGFR
Sources

GO Terms for Gastrointestinal System Cancer

About this section

Cellular components related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.56 ADAM17 CASP3 EGFR KRAS
2 cell-cell junction GO:0005911 9.26 ADAM17 AKT1 CTNNB1 KIT
3 flotillin complex GO:0016600 9.16 CDH1 CTNNB1
4 cell surface GO:0009986 9.1 ADAM17 CCR6 CDH1 EGFR KIT VEGFA

Biological processes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.97 AKT1 CTNNB1 EGFR HRAS TP53
2 negative regulation of gene expression GO:0010629 9.96 AKT1 CTNNB1 HRAS VEGFA
3 MAPK cascade GO:0000165 9.93 EGFR HRAS KIT KRAS
4 response to drug GO:0042493 9.93 ADAM17 CASP3 CCND1 CDH1 CTNNB1
5 positive regulation of gene expression GO:0010628 9.91 AKT1 CTNNB1 HRAS KIT KRAS TP53
6 negative regulation of apoptotic process GO:0043066 9.88 AKT1 CASP3 CTNNB1 EGFR TP53 VEGFA
7 positive regulation of cell migration GO:0030335 9.85 ADAM17 EGFR HRAS KIT VEGFA
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 AKT1 EGFR VEGFA
9 liver development GO:0001889 9.83 CCND1 EGFR KRAS
10 positive regulation of cell growth GO:0030307 9.82 ADAM17 AKT1 EGFR
11 cellular response to hypoxia GO:0071456 9.81 AKT1 MALAT1 TP53 VEGFA
12 Ras protein signal transduction GO:0007265 9.8 HRAS KRAS TP53
13 response to estradiol GO:0032355 9.8 CASP3 CCND1 CTNNB1 EGFR
14 cytokine-mediated signaling pathway GO:0019221 9.8 AKT1 CASP3 CCND1 KIT KRAS TP53
15 response to glucocorticoid GO:0051384 9.79 CASP3 CCND1 KRAS
16 response to organic substance GO:0010033 9.78 AKT1 CASP3 CCND1 CDH1
17 positive regulation of epithelial cell proliferation GO:0050679 9.77 EGFR HRAS VEGFA
18 cellular response to growth factor stimulus GO:0071363 9.76 AKT1 CTNNB1 EGFR
19 epidermal growth factor receptor signaling pathway GO:0007173 9.74 ADAM17 AKT1 EGFR
20 positive regulation of blood vessel endothelial cell migration GO:0043536 9.73 ADAM17 AKT1 VEGFA
21 positive regulation of MAPK cascade GO:0043410 9.7 CTNNB1 HRAS KIT
22 tongue development